Our RNA Design Services support pharmaceutical companies, biotechnology innovators, and advanced therapy developers in establishing robust RNA sequence architectures for therapeutic and research applications. RNA sequence design is a foundational step in the development of mRNA therapeutics, RNA vaccines, gene-silencing platforms, and gene-editing systems. Effective RNA engineering requires careful integration of codon optimization, untranslated region (UTR) design, secondary structure control, and immunogenicity risk management to ensure that RNA molecules function reliably in biological systems.
Our platform integrates bioinformatics-driven design workflows with experimental validation strategies to help enterprise research teams accelerate RNA program initiation while reducing downstream development risks. By combining sequence optimization algorithms, structural modeling, and practical development considerations such as manufacturability and delivery compatibility, we provide RNA design strategies aligned with the technical expectations of modern RNA therapeutic programs.
Translational Efficiency and Protein Expression: For mRNA and self-amplifying RNA programs, sequence architecture strongly influences translation efficiency. Codon usage, GC balance, secondary structure near the start codon, and optimized UTR elements all play critical roles in determining protein expression levels in mammalian systems. Our RNA design workflows evaluate these parameters to improve expression consistency while maintaining sequence stability.
Immunogenicity and Innate Immune Activation: RNA molecules can activate innate immune sensors such as TLRs, RIG-I, and MDA5 if certain sequence motifs or structural features are present. RNA design therefore requires careful motif screening, nucleotide modification planning, and structure evaluation to minimize unintended immune activation in therapeutic applications. Our design strategies incorporate sequence-level risk assessment and modification planning consistent with current RNA therapeutic development practices.
Structural Stability and RNA Integrity: RNA folding patterns influence both stability and translational performance. Excessive secondary structures can reduce ribosome accessibility, while unstable sequences may degrade rapidly in biological environments. Our design approach integrates RNA folding prediction tools and structural analysis to balance stability, translational accessibility, and manufacturability.
Target Specificity in Gene-Silencing Platforms: For siRNA and antisense oligonucleotide programs, precise sequence design is essential to ensure effective target engagement while minimizing off-target effects. Advanced design workflows evaluate thermodynamic properties, target accessibility, and sequence homology across the transcriptome to support high-specificity gene silencing strategies.
Compatibility with Delivery and Manufacturing Platforms: RNA sequences must ultimately be compatible with downstream synthesis, purification, and delivery technologies such as lipid nanoparticles or conjugate-based delivery systems. Our RNA design services incorporate considerations for IVT production feasibility, modification strategies, and formulation compatibility to support efficient transition from sequence design to experimental development.
Our RNA design services support biotechnology companies, pharmaceutical developers, and advanced therapy research teams in building optimized RNA constructs for therapeutic and experimental applications. RNA sequence architecture directly influences expression efficiency, stability, target specificity, and manufacturability. As RNA technologies continue to expand across vaccines, protein replacement therapies, gene silencing platforms, and genome editing systems, robust RNA design strategies have become essential to the success of early-stage development programs.
Our platform integrates bioinformatics modeling, sequence engineering strategies, and translational development considerations to support enterprise research teams throughout the RNA design phase. By combining computational prediction tools with practical experience in RNA therapeutic development, we help clients develop RNA constructs that are compatible with modern delivery systems, scalable synthesis workflows, and downstream regulatory expectations.
A structured overview of modality-specific RNA design capabilities and the decision parameters enterprise teams use to evaluate sequence architecture, feasibility, and target fit across leading RNA therapeutic platforms.
| RNA Modality | Primary Design Objective | Key Design Parameters | Primary Risk Areas | Typical Enterprise Applications |
| mRNA | Maximize protein expression with controlled innate immune activation | CDS codon usage, 5′/3′ UTR architecture, GC balance, local structure near AUG, poly(A) strategy | Unwanted innate sensing, inhibitory secondary structure, expression variability across cell types | Vaccines, protein replacement, oncology antigens, cell engineering |
| Self-Amplifying RNA (saRNA) | Optimize replicase-driven amplification and antigen/protein expression output | Replicase/cassette organization, length constraints, subgenomic elements, structural stability | Size-driven delivery constraints, replication/expression balance, innate activation risk | Dose-sparing vaccines, durable antigen expression platforms |
| Circular RNA (circRNA) | Enable durable expression using circular transcript architecture | Circularization elements, translation initiation design (IRES or alternative), junction design, structure | Translation efficiency uncertainty, circularization efficiency constraints, junction liabilities | Longer-duration protein expression, exploratory next-gen RNA therapeutics |
| siRNA | Achieve potent, specific mRNA knockdown with minimal off-targeting | Target site selection, duplex thermodynamics, seed-region behavior, strand bias, sequence uniqueness | Seed-mediated off-target effects, variable target accessibility, immune-stimulatory motifs | Gene silencing, target validation, liver-focused therapeutic programs |
| Antisense Oligonucleotide (ASO) | Drive RNase H knockdown or splice modulation with high selectivity | Target accessibility, binding affinity, gapmer vs steric-blocking choice, chemistry planning | Hybridization off-targets, tolerability risk, isoform complexity, splice context variability | Splice modulation, CNS/rare disease programs, mechanism-of-action studies |
| Guide RNA (gRNA/sgRNA) | Maximize on-target editing while minimizing genome-wide off-target activity | PAM proximity, guide sequence features, predicted editing efficiency, off-target homology profile | Off-target edits, locus accessibility variability, assay-dependent performance differences | CRISPR screening, ex vivo cell therapy engineering, target discovery |
Enterprise RNA programs rely on pre-experimental computational analysis to de-risk sequence choices, prioritize candidates, and align designs with known biological constraints such as translation dynamics, innate immune sensing, and off-target liabilities.
| Design Analysis Category | Objective | Typical Approaches | Applicable RNA Modalities | Stage Alignment |
| Codon & Composition Optimization | Improve translational efficiency and expression consistency | Codon usage analysis, GC balance review, motif avoidance rulesets | mRNA, saRNA, circRNA | Discovery |
| UTR & Regulatory Element Design | Enhance translation initiation and mRNA stability behaviors | UTR selection strategies, regulatory motif review, comparative architecture evaluation | mRNA, saRNA, circRNA | Discovery |
| RNA Secondary Structure & Accessibility Modeling | Reduce inhibitory structures and improve functional accessibility | Folding prediction, local structure scanning near initiation regions, accessibility mapping | mRNA, saRNA, circRNA; target accessibility for siRNA/ASO | Discovery |
| Translation Efficiency Risk Review | Identify sequence features correlated with poor expression output | Initiation context checks, structure/sequence heuristics, expression risk scoring (program-dependent) | mRNA, saRNA, circRNA | Discovery / Early Development |
| Innate Immune Activation Risk Screening | Reduce likelihood of unintended sensing in therapeutic contexts | Motif scanning associated with RNA sensors, structural red flags, modification planning inputs | mRNA, saRNA, circRNA; selected oligos as applicable | Discovery / Preclinical Planning |
| Off-Target Screening (Transcriptome / Genome) | Minimize unintended binding or editing events | Homology screening, mismatch-tolerant alignment, seed-region off-target evaluation | siRNA, ASO, gRNA/sgRNA | Discovery |
| Target Region & Isoform Context Review | Ensure design aligns with biologically relevant isoforms and target regions | Isoform mapping, exon junction review, transcript annotation checks | siRNA, ASO; gRNA depending on edit strategy | Discovery |
| Chemistry / Modification Strategy Inputs | Support stability and tolerability goals while preserving activity | Fit-for-purpose modification planning, chemistry constraints review (platform-dependent) | mRNA/saRNA/circRNA; siRNA; ASO | Discovery / Lead Optimization Planning |
This workflow reflects how enterprise teams typically execute RNA design programs from target definition through design handoff for experimental validation. It is structured to ensure traceability, scientific rigor, and decision transparency—integrating computational analysis, expert review, and documented design rationale aligned with current RNA therapeutic development practices. Each milestone is supported by platform methodology (defined rulesets, version-controlled design iterations, and risk screening) and expert validation inputs (bioinformatics, RNA biology, and translational development perspectives).
Confirm therapeutic intent (expression, silencing, splice modulation, editing), target biology, species context, and assay plans. Review transcript/isoform landscape and define modality fit (mRNA/saRNA/circRNA/siRNA/ASO/gRNA). Establish acceptance criteria for candidate selection and align on documentation requirements (sequence annotation format, traceability expectations, and handoff package structure).
Select the platform methodology appropriate to the modality and program stage: codon/UTR strategy for expression constructs; target-site selection and thermodynamic rules for siRNA; binding and chemistry planning logic for ASOs; efficiency and off-target scoring frameworks for gRNA/sgRNA. Define constraints (length, sequence exclusions, motif avoidance, modification strategy assumptions) and establish a version-controlled design plan to ensure reproducibility across iterations.
Generate a candidate set using defined rulesets and computational pipelines. For mRNA/saRNA/circRNA, build construct architecture (CDS, regulatory elements, and structure-aware design choices). For siRNA/ASO, generate target-region candidates with accessibility-informed site selection. For CRISPR, identify PAM sites and generate guide candidates. Each candidate is tagged with structured metadata to preserve design provenance and assumptions.
Perform risk screening consistent with enterprise expectations: off-target homology screening (transcriptome/genome as applicable), innate immune activation motif review for IVT-derived RNAs, and secondary-structure/accessibility analysis to identify likely performance constraints. Apply fit-for-purpose modification planning inputs (where relevant) and document identified risks with mitigation recommendations in a structured risk register format.
Conduct expert validation through multidisciplinary review (bioinformatics, RNA biology, and translational considerations) to confirm that candidate ranking aligns with program intent and known modality constraints. Produce a prioritized shortlist with a rationale that is auditable and actionable, including recommended validation assay readouts (e.g., expression confirmation approaches, knockdown endpoints, editing outcome measures) and suggested controls for interpreting early data.
Deliver a complete RNA design handoff package suitable for internal R&D execution: annotated sequences, candidate IDs, version history, decision rationale, screening summaries, and a final ranked set with usage notes. Documentation is structured to support enterprise collaboration, downstream experiment reproducibility, and internal governance needs (traceable assumptions, clear constraints, and standardized reporting).
Our RNA design services are structured to support biotechnology companies, pharmaceutical developers, and advanced therapy research teams seeking reliable sequence engineering expertise. RNA construct architecture strongly influences expression efficiency, specificity, stability, and downstream development success. Our platform integrates computational design workflows with expert review processes to ensure that RNA constructs are optimized not only for theoretical performance but also for practical experimental execution.
RNA engineering technologies are widely applied across modern biomedical research and therapeutic development, where optimized RNA sequence design enables reliable gene expression, targeted gene silencing, and precise genome editing in experimental and translational studies.
Whether you are initiating a new RNA therapeutic program, optimizing sequence architecture for improved expression, or designing RNA constructs for gene silencing or genome editing applications, our RNA design services provide the technical expertise needed to support early-stage research and development. Our specialists collaborate closely with biotechnology companies, pharmaceutical developers, and academic research teams to evaluate project objectives, recommend appropriate RNA design strategies, and generate optimized candidate sequences aligned with experimental and translational goals. From target analysis and sequence engineering to candidate prioritization and documentation delivery, our platform is structured to help research teams move efficiently from concept to experimental validation. Contact us to discuss your RNA design requirements and explore how our experts can support your next RNA research initiative.
RNA design is the process of creating RNA sequences with predictable structures and functions using computational and experimental methods. It is critical for developing stable, efficient, and specific RNA molecules for therapeutics, vaccines, diagnostics, and synthetic biology.
We typically require details about your research goal (e.g., therapeutic target, vaccine antigen, diagnostic application), technical requirements (such as stability, codon optimization, or delivery method), and any constraints relevant to your project.
Beyond computational design, we can support in vitro RNA synthesis and functional validation to ensure your sequences meet performance expectations.
RNA design improves stability and efficiency through codon optimization, GC content balancing, UTR engineering, and chemical modifications, which enhance translation and reduce degradation.
Yes, RNA design services can create optimized guide RNA (gRNA/sgRNA) sequences for CRISPR systems, improving targeting accuracy while minimizing off-target effects.
